Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Datametrex Graph Blockchain Announces Collaboration Agreement With Revive Therapeutics to Develop a Patient Data Blockchain Platform

V.DM, C.RVV

TORONTO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV:DM) (FSE:D4G) is pleased to announce that its subsidiary company Graph Blockchain Limited has signed a Collaboration Agreement with Revive Therapeutics Ltd. ("Revive") (TSXV:RVV) (OTCQB:RVVTF) to develop the blockchain component in Revive’s proprietary patient-focused program enabled by artificial intelligence (“AI”) dedicated to the medical cannabis industry.

This agreement is in addition to the previously announced contract between Nexalogy and Revive on November 27, where Nexalogy will use its proprietary social data discovery solution, NexaIntelligence, to unlock the value of data related to medical cannabis collected from social media networks and internet environments such as discussion forums, blogs and news sites.  

“The collaboration with Graph Blockchain complements our current relationship with Datametrex’s AI subsidiary, Nexalogy, and is an important piece of our plan in building our concept of a patient-focused platform enabled by AI for the medical cannabis industry,” said Fabio Chianelli, President of Revive.

Andrew Ryu, Chairman and CEO of Datametrex AI stated, “We are thrilled to sign a second contract with Revive and look forward to developing a complete package of Blockchain and Artificial Intelligence solutions for them. This is an explosive area and our solutions will assist Revive in delivering vital data for patients. We are in talks with a number of Marijuana Licensed Producers and see an opportunity for Datametrex AI and Graph Blockchain solutions to become the leader in providing these solutions for the Cannabis sector.”

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors.

Additional information on Revive is available at: www.ReviveThera.com.

About the Company

Datametrex AI Limited is focused on the collection of retail sales data, providing Government Agencies and Fortune 500 corporations with Artificial Intelligence solutions and implementing Blockchain technology for secure Data Transfers and Cryptocurrency Mining.

Additional information on Datametrex is available at: www.datametrex.com.

To stay informed about Datametrex, please join our Investor Group on 8020 Connect http://bit.ly/2fPUNwF for all upcoming news releases, articles comments and questions.

For further information, please contact:

Jeffrey Stevens – President & COO
Phone: (647) 400-8494
Email: jstevens@datametrex.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release includes certain forward-looking statements within the meaning of Canadian securities laws. Such forward-looking information and statements are not representative of historical facts or information or current condition, but instead represent only the Company`s belief regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

Generally, such forward-looking information or statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

The forward-looking information contained herein includes, but is not limited to, information with respect to prospective financial performance, anticipated capital funding and sources, proposed or potential acquisitions, estimated operating and sales costs, estimated market drivers and demand, business prospects and strategy, new markets for growth and financial position. By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Accordingly, readers should not place undue reliance on any forward-looking information or statements contained in this press release.

The forward-looking information contained in this press release is made as of the date hereof, and the Company does not undertake to update any forward-looking information that is contained or referenced herein, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. All subsequent written and oral forward looking information and statements attributable to the Company or persons acting on its behalf are expressly qualified in its entirety by this notice.

Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today